Physician profile
Abdullah Khan
NPI 1083877666
$9,739.70
in general payments reported to CMS, 2019-2025
47 companies · $268 in 2025
The $268 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,195 · 2020: $1,201 · 2021: $1,036 · 2022: $1,505 · 2023: $1,240 · 2024: $1,296 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,803.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $2,523.18 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $821.91 | 2019-2024 | Lifevest |
| Inari Medical, INC. | $743.76 | 2021-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Janssen Pharmaceuticals, INC | $551.91 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $544.37 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Varithena Administration Pack |
| Medtronic, INC. | $500.92 | 2021-2023 | Onyx Frontier, Symplicity G3 |
| Abbott Laboratories | $338.01 | 2019-2024 | Confirm Rx, Xience Skypoint, Aveir |
| Merck Sharp & Dohme LLC | $336.69 | 2021-2024 | Verquvo |
| Abiomed | $324.93 | 2023-2024 | Impella |
| E.R. Squibb & Sons, L.L.C. | $264.28 | 2019-2023 | Camzyos |
| Novartis Pharmaceuticals Corporation | $250.79 | 2019-2025 | |
| Pfizer INC. | $222.05 | 2020-2024 | |
| Astrazeneca Pharmaceuticals LP | $213.70 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $204.94 | 2020-2024 | Amvuttra |
| Medtronic Vascular, INC. | $196.25 | 2020 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $194.42 | 2020-2023 | Xtandi |
| Kestra Medical Technology Services, INC. | $126.34 | 2024 | Assure Wcd |
| Terumo Medical Corporation | $125.00 | 2020 | |
| Sk Life Science, INC. | $109.37 | 2022 | |
| Janssen Scientific Affairs, LLC | $101.29 | 2019-2022 | |
| W. L. Gore & Associates, INC. | $94.89 | 2025 | Gore Propaten Vascular Graft |
| Daiichi Sankyo INC. | $87.27 | 2022-2024 | Injectafer |
| Asahi Intecc USA, INC. | $79.21 | 2021-2024 | Peripheral Vascular |
| Actelion Pharmaceuticals US, INC. | $75.12 | 2020-2024 | Opsumit, Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $63.89 | 2022 | |
| Z-Medica, LLC | $61.59 | 2019 | |
| Imperative Care, INC | $60.04 | 2024 | Symphony Catheter |
| Amgen INC. | $57.90 | 2025 | Repatha |
| Shockwave Medical, INC | $55.55 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Bardy Diagnostics, INC. | $46.49 | 2022 | |
| Amarin Pharma, INC. | $42.23 | 2019 | |
| Arbor Pharmaceuticals, INC. | $34.76 | 2019 | |
| Cardinal Health 200 LLC | $33.75 | 2021 | |
| Teleflex LLC | $28.80 | 2023 | Vascband |
| Esperion Therapeutics, INC. | $24.04 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $22.58 | 2023 | Inpefa |
| United Therapeutics Corporation | $21.62 | 2023 | Tyvaso, Orenitram |
| Chiesi USA, INC. | $20.84 | 2024 | Kengreal |
| Glaxosmithkline, LLC. | $20.08 | 2022 | |
| Stryker Corporation | $17.86 | 2022 | |
| Ethicon US, LLC | $17.56 | 2024 | Ethicon, Surgiflo Hemostatic Matrix, Vistaseal |
| Cleerly, INC. | $16.28 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Lundbeck LLC | $15.16 | 2019 | |
| Baxter Healthcare | $14.81 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Scpharmaceuticals INC. | $13.95 | 2023 | |
| Medtronic USA, INC. | $12.44 | 2020 | |
| Nuwellis, INC. | $6.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdullah Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.